How do you keep supply chains compliant when dealing with divergent regulatory frameworks for gene therapies across the US, EU, and the Asia-Pacific regions?

Yeah.

So the, the key point here is that compliance cannot be inspected, um, into supply chain.

So you can't, you can't add it at the very end.

It has to be designed end-to-end supply chain.

So the way I, I categorize it is, is the plan, source, make, deliver.

And, yeah, all these four buckets, you have to design your, uh, compliance in, into these.

So, uh, looking ahead for three to five years as new modalities like mRNA, radiopharmaceuticals, or antibody-drug conjugates gain traction, what supply chain capabilities should biopharma companies be building today to be ready for tomorrow?

So how do we build a team? Well, I was

starting something in India.

I didn't know anyone

I would just focus more on what I'm most passionate about and just go from there next question

hello monies i am arvind singh from agra my question is to you is that why don't you teach your students how to make money through stock market or investment like you do instead of focusing only on studies